Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN known ✓ | P00797 | 2/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4134751 | 1.00 | REN (0.36) | RENP2RX7NAMPTCYP2C9TMEM97 | |
| Fumaric Acid SCHEMBL4137848 | 0.89 | CNR1 (0.36) | RENNAMPTCNR1SLC16A3SLC16A1 | |
| Fumaric Acid SCHEMBL4137854 | 0.89 | CNR1 (0.36) | RENNAMPTCNR1SLC16A3SLC16A1 | |
| Fumaric Acid SCHEMBL4131538 | 0.87 | SLC16A3 (0.36) | RENNAMPTHTR6CNR1SLC16A3 | |
| Fumaric Acid SCHEMBL4131542 | 0.87 | SLC16A3 (0.36) | RENNAMPTHTR6CNR1SLC16A3 | |
| Fumaric Acid SCHEMBL4131318 | 0.84 | NAMPT (0.35) | NAMPTCYP2C9CNR1SLC16A3SLC16A1 | |
| Fumaric Acid SCHEMBL4131328 | 0.84 | NAMPT (0.35) | NAMPTCYP2C9CNR1SLC16A3SLC16A1 | |
| Fumaric Acid SCHEMBL3701699 | 0.84 | NAMPT (0.37) | P2RX7NAMPTCACNA1GCACNA1H | |
| Fumaric Acid SCHEMBL3701692 | 0.84 | NAMPT (0.37) | P2RX7NAMPTCACNA1GCACNA1H | |
| Fumaric Acid SCHEMBL3691572 | 0.82 | SLC16A3 (0.36) | P2RX7HTR6CNR1SLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | REN 1158/4885KCNH2 3538/4885MEN1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.